Access to peginterferon plus ribavirin therapy for hepatitis C in Romania between 2002-2009

Journal of Gastrointestinal and Liver Diseases

Volumn 19, Issue 2, 2010, Pages 161-167

  Gheorghe, Liana ^a   Pascu, Oliviu ^b   Ceausu, Emanoil ^c   Csiki, Irma Eva ^d   Iacob, Speranta ^a   Caruntu, Florin ^e   Simionov, Iulia ^a   Vadan, Roxana ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^e 'Prof Dr Matei Bals' National Institute for Infectious Diseases   (Romania)

Author keywords

Hepatitis C; Peginterferon; Ribavirin; Therapy

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; CHRONIC HEPATITIS; DRUG COST; EVIDENCE BASED PRACTICE; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PREVALENCE; REIMBURSEMENT; ROMANIA; VIRUS HEPATITIS; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; AWARENESS; DRUG COSTS; DRUG THERAPY, COMBINATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C, CHRONIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INTERFERON-ALPHA; PHYSICIAN'S PRACTICE PATTERNS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REFERRAL AND CONSULTATION; RIBAVIRIN; ROMANIA; TIME FACTORS;

EID: 77954681429     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C infection. Lancet Infect Dis 2005; 5: 558-567.
3. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36: S3-S20.
4. Freeman RB Jr, Steffick DE, Guidinger MK, Farmer DG, Berg CL, Merion RM. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008; 8: 958-976.
5. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serang HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-1380.
6. Lettmeier B, Muhlberger N, Schwarzer R, et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 2008; 49: 528-536.
7. Gheorghe L, Iacob S, Csiki IE. Prevalence of hepatitis C in Romania: Different from European rates. J Hepatol 2008; 49: 661-662.
8. EASL International Consensus Conference on hepatitis C, Paris, 26-27 February 1999. Consensus statement. J Hepatol 1999; 31: 3-8.
9. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
10. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
11. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2007; 25:1153-1162.
12. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
13. Grigorescu M; Romanian Society of Gastroenterology and Hepatology. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis 2009; 18:45-50.
14. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 754-758.
15. Kanwal W, Hoang T, Spiegel B, et al. Predictors of treatment in patients with chronic hepatitis C infection-role of patient versus nonpatient factors. Hepatology 2007; 46:1741-1749.
16. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750-1755.
17. Gheorghe L, Csiki IE, Iacob S, Gheorghe C, Smira G, Regep L. The prevalence and risk factors of hepatitis C virus infection in adult population in Romania: A nationwide survey 2006-2008. J Hepatol 2010 (accepted for publication).
18. Hatem C, Minello A, Bresson-Hadni S, et al. Is the management of hepatitis C patients appropriate? A population-based study. Aliment Pharmacol Ther 2005; 21: 1007-1015.
19. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat 2001; 8: 377-383.
20. Doucette KE, Robson V, Shafran S, Kunimoto D. Improving access to care by allowing self-referral to a hepatitis C clinic. Can J Gastroenterol. 2009;23:421-424.